Unusually long remission in two patients with follicular lymphoma receiving immunomodulating therapeutic cancer vaccines
Leukemia Research Reports · 2026 · 26 · 100604
DOI: 10.1016/j.lrr.2026.100604 ↗Kurz gefasst
Fallbericht in der Zeitschrift Leukemia Research Reports, 2026. Verfasst von Morten Orebo Holmström und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immune Therapy, Department of Oncology, Herlev-Gentofte Hospital, Herlev, Denmark. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gentofte Hospital, Herlev Hospital.
Abstract (Originalsprache)
The immune checkpoints programmed death-ligand (PD-L)1 and PD-L2 are expressed in follicular lymphoma (FL), yet immune checkpoint blocking antibodies have failed in FL. We previously initiated a phase I immune modulating vaccination (IMV) trial targeting PD-L1 and PD-L2 in patients with advanced follicular lymphoma. The study suggested a clinical effect of the vaccine, however due to relatively short follow-up time and a heterogeneous patient population no clear conclusions could be made after the trial. In this study we present follow-up data on the eight patients included in the trial. Notably, two patients displayed an unusual disease history after completion of the vaccination trial. One patient had experienced two relapses at two years after diagnosis, then received vaccines after third line therapy and subsequently remained treatment-free for five years after vaccinations. The other patient who entered the vaccine trial after third line therapy remains in complete response at 6.5 years after the vaccination trial. Longitudinal immune monitoring in these two patients demonstrated persistent, functionally active vaccine-specific CD4⁺ and CD8⁺ T-cell responses years after vaccine completion. These results suggest a disease modifying effect of targeting PD-L1 and PD-L2 by IMV in FL. Trial registration number: NCT03381768. Date of registration: December 22, 2017.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Center for Cancer Immune Therapy, Department of Oncology, Herlev-Gentofte Hospital, Herlev, Denmark.
- Department of Immunology and Microbiology, Copenhagen University, Copenhagen, Denmark.
- Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
- Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Förderung
- Gentofte Hospital
- Herlev Hospital
Zitieren
APA
Holmström, M. O., Ahmad, S. M., Klausen, U., Bjørn, M. E., Gang, A. O., El-Galaly, T. C., Pedersen, L. M., & Andersen, M. H. (2026). Unusually long remission in two patients with follicular lymphoma receiving immunomodulating therapeutic cancer vaccines. Leukemia Research Reports, 26, 100604. https://doi.org/10.1016/j.lrr.2026.100604
Vancouver
Holmström MO, Ahmad SM, Klausen U, Bjørn ME, Gang AO, El-Galaly TC, et al. Unusually long remission in two patients with follicular lymphoma receiving immunomodulating therapeutic cancer vaccines. Leukemia Research Reports. 2026;26:100604. doi:10.1016/j.lrr.2026.100604
BibTeX
@article{Holmstrm2026,
author = {Holmström, Morten Orebo and Ahmad, Shamaila Munir and Klausen, Uffe and Bjørn, Mads Emil and Gang, Anne Ortved and El-Galaly, Tarec Christoffer and Pedersen, Lars Møller and Andersen, Mads Hald},
title = {Unusually long remission in two patients with follicular lymphoma receiving immunomodulating therapeutic cancer vaccines},
journal = {Leukemia Research Reports},
year = {2026},
volume = {26},
pages = {100604},
doi = {10.1016/j.lrr.2026.100604}
}
EUVIMED